Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 11 Jun 2013 |
| Orion Corporation issues a EUR 150 million domestic bond on 11 June 2013 | 4 Jun 2013 |
| Orion Diagnostica's statutory co-operation negotiations completed | 3 Jun 2013 |
| 225,000 Orion A-shares converted into B-shares | 20 May 2013 |
| Orion Corporation is preparing to issue a bond | 20 May 2013 |